Lexaria Bioscience to Launch New Clinical Study Comparing Enhanced Oral GLP-1 Formulations to Market Leaders

Lexaria Bioscience Corp. has engaged a contract research organization to conduct Human Pilot Study #7, a five-week parallel group investigation comparing two oral DehydraTECH-semaglutide compositions to commercially available Wegovy tablets. The study will assess safety, tolerability, and pharmacokinetic properties under fasted pre-dose conditions, with ethics approval submissions currently being prepared.

The research represents significant innovation as it introduces two main improvements to Lexaria’s technology. For the first time, the company is using an oral tablet DHT-sema composition, attempting to mimic certain delivery properties of Novo Nordisk’s Rybelsus and Wegovy tablets. Both the tablet and capsule test articles will be formulated with salcaprozate sodium (SNAC) and evaluated over a multi-dose, multi-week period, unlike earlier single-dose studies conducted in 2024 and 2025.

Lexaria aims to preserve the superior safety and tolerability profiles demonstrated in previous GLP-1 studies while achieving pharmacokinetic performance that matches or exceeds commercial oral tablet brands. The five-week duration is designed to reach steady-state drug concentrations in the body, providing more comprehensive data than earlier research. If successful, the study results will contribute to an existing data set intended to generate interest from pharmaceutical partners seeking commercial relationships involving Lexaria’s proprietary technology.

The company will update stakeholders once ethics board approval is obtained, allowing patient recruitment to begin. The study is fully funded from existing corporate resources. For more information about Lexaria’s technology platform, visit www.lexariabioscience.com. The original announcement can be viewed at www.newmediawire.com.

This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Lexaria Bioscience to Launch New Clinical Study Comparing Enhanced Oral GLP-1 Formulations to Market Leaders.

The post Lexaria Bioscience to Launch New Clinical Study Comparing Enhanced Oral GLP-1 Formulations to Market Leaders appeared first on citybuzz.